Faster turnaround for breast cancer test:
This article was originally published in Clinica
Ortho-Clinical Diagnostics has added a new test for monitoring breast cancer to its fully-automated VITROS ECi immunodiagnostic system. The Raritan, New Jersey based company has incorporated into its system Centocor Diagnostic's CA 15-3 assay for monitoring the breast cancer marker DF3-defined antigen in patients following surgery and during radiation or chemotherapy. Running the assay on the ECi system can produce results in as little as 43 minutes, said Ortho.
You may also be interested in...
Tensions between industry and the European Commission on the issue of health claims for botanical food supplements were aired on the second day of the BAH's High Level Conference on the Future of Medicines, with the EC saying the EU Green Deal is now higher up on its list of priorities for the foreseeable future.
Issues over supply and the use of a skinny label have the potential to take a toll on the market for the fish oil drug icosapent ethyl, one analyst has claimed in the wake of Hikma’s recent generic launch.
The German Bundestag has adopted the Unified Patent Court’s draft ratification bill with the necessary qualified majority.